Moving towards Personalized Medicine in Muscle-Invasive Bladder Cancer: Where Are We Now and Where Are We Going?

Moving towards Personalized Medicine in Muscle-Invasive Bladder Cancer: Where Are We Now and Where Are We Going?

Neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy is the recommended treatment, with the highest level of evidence, for patients with muscle-invasive bladder cancer (MIBC). However, only a minority of patients receive this treatment, mainly due to patient comorbidities, the rel...

Full description

Bibliographic Details
Main Authors: Juan Carlos Pardo, Vicenç Ruiz de Porras, Andrea Plaja, Cristina Carrato, Olatz Etxaniz, Oscar Buisan, Albert Font
Format: Article
Language:English
Published: MDPI AG 2020-08-01
Series:International Journal of Molecular Sciences
Subjects:
muscle-invasive bladder cancer
chemotherapy
immunotherapy
personalized medicine
predictive biomarker
Online Access:https://www.mdpi.com/1422-0067/21/17/6271

Internet

https://www.mdpi.com/1422-0067/21/17/6271

Similar Items